A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

The primary objective of the study is to evaluate the efficacy of 2 different maintenancedose regimens of TEV‐48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adultparticipants with inflammatory bowel disease (IBD).Secondary objectives of the study are to: ‐ evaluate the efficacy of 2 different maintenance dose regimens of TEV‐48574 scadministered Q4W in adult participants with IBD ‐ evaluate the safety and tolerability of 2 different maintenance dose regimens ofTEV‐48574 sc administered Q4W in adult participants with IBD ‐ evaluate the immunogenicity of 2 different maintenance dose regimens of TEV‐48574 scadministered Q4W in adult participants with IBDThe total duration for a participant in the double‐blind period only is 66 weeks; and fora participant in the open‐label extension (OLE) period, up to an additional 268 weeks.